A Phase 4 interventional study of PNEUMOVAX™ 23 in Pneumococcal Infection, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 70 Years to 89 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-30.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing 23-valent pneumococcal capsular polysaccharide vaccine in Pneumococcal Infections — 1 open to participants now, 1 under way, 1 of them phase 3. 23-valent pneumococcal capsular polysaccharide vaccine · Pneumococcal Infections.
Among the 15 studies testing 23-valent pneumococcal capsular polysaccharide vaccine in Pneumococcal Infections, this one is the 8th largest by enrollment, is one of 4 that started in 2014, is one of 5 in phase 4, and was the 9th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →1 of the 15 studies testing 23-valent pneumococcal capsular polysaccharide vaccine in Pneumococcal Infections is open now, in 1 country. Recruiting first, the newest first:
Aimei Vacin BioPharm (Zhejiang) Co., Ltd. · Sites in China
Ages 2+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 70 Years to 89 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 4 started in 2014.
This study's enrollment of 243 is below the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 243 across the 15 interventional studies. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
43 studies in Pneumococcal Infections by Merck & Co., Inc: 1 open now, 1 under way, none of them phase 3. Of 42 finished, 40 (95%) have results posted.
Among the 43 studies in Pneumococcal Infections by Merck & Co., Inc, this one is the 33rd largest by enrollment, is one of 3 that started in 2014, is the only one in phase 4, and was the 11th registered.
Merck & Co., Inc’s Pneumococcal Infections studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing 23-valent pneumococcal capsular polysaccharide vaccine in Pneumococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 43 in Pneumococcal Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if revaccination with pneumococcal vaccine (PNEUMOVAX™ 23, V110) is well tolerated and produces an immune response in older Japanese adults. The primary hypothesis being tested is that the geometric mean concentration of antibodies to pneumococcal polysaccharide serotypes 3, 6B, and 23F at 4 weeks after revaccination will be superior to that before revaccination in Japanese adults who received a primary vaccination at least 5 years before revaccination.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who received an initial vaccination at least 5 years prior
Biological: PNEUMOVAX™ 23
0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who have never received PNEUMOVAX™ 23 vaccination
Biological: PNEUMOVAX™ 23
Drug page: 23-valent pneumococcal capsular polysaccharide vaccine
PNEUMOVAX™ 23 (23-Valent Pneumococcal Polysaccharide Vaccination, V110, PPV23)
Change From Baseline in Serotype-Specific Antibody Geometric Mean Concentration at 4 Weeks After Revaccination
Serum antibodies to pneumococcal serotypes were measured by enzyme-linked immunosorbent assays. Geometric mean antibody concentrations (GMCs) were calculated at Baseline and 4 weeks postvaccination. Geometric Mean Fold Rise was the GMC at 4 weeks after vaccination minus the GMC at Baseline.
Time frame: Baseline and 4 weeks after revaccination
Change From Baseline in Serotype-Specific Antibody Geometric Mean Concentration at 4 Weeks After Primary Vaccination
Serum antibodies to pneumococcal serotypes were measured by enzyme-linked immunosorbent assays. Geometric mean antibody concentrations (GMCs) were calculated at Baseline and 4 weeks postvaccination. Geometric Mean Fold Rise was the GMC at 4 weeks after vaccination minus the GMC at Baseline.
Time frame: Baseline and 4 weeks after primary vaccination
Percentage of Participants With an Adverse Event of Injection-site Erythema
An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of injection-site erythema recorded on the Vaccine Report Card (VRC) during the first 5 days after vaccination was recorded.
Time frame: Up to 5 days after vaccination
Percentage of Participants With an Adverse Event of Injection-site Swelling
An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of injection-site swelling recorded on the VRC during the first 5 days after vaccination was recorded.
Time frame: Up to 5 days after vaccination
Percentage of Participants With an Adverse Event of Injection-site Pain
An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of injection-site pain recorded on the VRC during the first 5 days after vaccination was recorded.
Time frame: Up to 5 days after vaccination
Percentage of Participants With an Adverse Event of Pyrexia
Percentage of participants with an adverse event of pyrexia (\>=37.5°C, oral) recorded on the VRC during the first 5 days after vaccination was recorded.
Time frame: Up to 5 days after vaccination
Percentage of Participants With an Adverse Event of Myalgia
An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of myalgia recorded on the VRC during the first 14 days after vaccination was recorded.
Time frame: Up to 14 days after vaccination
Percentage of Participants With an Adverse Event of Arthralgia
An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of arthralgia recorded on the VRC during the first 14 days after vaccination was recorded.
Time frame: Up to 14 days after vaccination
Percentage of Participants With an Adverse Event of Headache
An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of headache recorded on the VRC during the first 14 days after vaccination was recorded.
Time frame: Up to 14 days after vaccination
Percentage of Participants With an Adverse Event of Fatigue
An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of fatigue recorded on the VRC during the first 14 days after vaccination was recorded.
Time frame: Up to 14 days after vaccination
| Milestone | Revaccination Group | Primary Vaccination Group |
|---|---|---|
| Started | 161 | 82 |
| Completed | 161 | 81 |
| Not completed | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
Serum antibodies to pneumococcal serotypes were measured by enzyme-linked immunosorbent assays. Geometric mean antibody concentrations (GMCs) were calculated at Baseline and 4 weeks postvaccination. Geometric Mean Fold Rise was the GMC at 4 weeks after vaccination minus the GMC at Baseline.
| Geometric Mean Fold Rise | Revaccination Group |
|---|---|
| Serotype 3: n=161 | 2.72 (2.35 to 3.14) |
| Serotype 6B: n=161 | 2.27 (2.02 to 2.55) |
| Serotype 23F: n=160 | 2.40 (2.12 to 2.72) |
Serum antibodies to pneumococcal serotypes were measured by enzyme-linked immunosorbent assays. Geometric mean antibody concentrations (GMCs) were calculated at Baseline and 4 weeks postvaccination. Geometric Mean Fold Rise was the GMC at 4 weeks after vaccination minus the GMC at Baseline.
| Geometric Mean Fold Rise | Primary Vaccination Group |
|---|---|
| Serotype 3 | 4.01 (3.17 to 5.08) |
| Serotype 6B | 5.83 (4.41 to 7.69) |
| Serotype 23F | 6.11 (4.65 to 8.02) |
An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of injection-site erythema recorded on the Vaccine Report Card (VRC) during the first 5 days after vaccination was recorded.
| Percentage of participants | Revaccination Group | Primary Vaccination Group |
|---|---|---|
| Percentage of Participants With an Adverse Event of Injection-site Erythema | 35.4 | 14.8 |
An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of injection-site swelling recorded on the VRC during the first 5 days after vaccination was recorded.
| Percentage of participants | Revaccination Group | Primary Vaccination Group |
|---|---|---|
| Percentage of Participants With an Adverse Event of Injection-site Swelling | 38.5 | 17.3 |
An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of injection-site pain recorded on the VRC during the first 5 days after vaccination was recorded.
| Percentage of participants | Revaccination Group | Primary Vaccination Group |
|---|---|---|
| Percentage of Participants With an Adverse Event of Injection-site Pain | 62.7 | 46.9 |
Percentage of participants with an adverse event of pyrexia (\>=37.5°C, oral) recorded on the VRC during the first 5 days after vaccination was recorded.
| Percentage of participants | Revaccination Group | Primary Vaccination Group |
|---|---|---|
| Percentage of Participants With an Adverse Event of Pyrexia | 6.8 | 1.2 |
An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of myalgia recorded on the VRC during the first 14 days after vaccination was recorded.
| Percentage of participants | Revaccination Group | Primary Vaccination Group |
|---|---|---|
| Percentage of Participants With an Adverse Event of Myalgia | 0.0 | 0.0 |
An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of arthralgia recorded on the VRC during the first 14 days after vaccination was recorded.
| Percentage of participants | Revaccination Group | Primary Vaccination Group |
|---|---|---|
| Percentage of Participants With an Adverse Event of Arthralgia | 0.0 | 0.0 |
An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of headache recorded on the VRC during the first 14 days after vaccination was recorded.
| Percentage of participants | Revaccination Group | Primary Vaccination Group |
|---|---|---|
| Percentage of Participants With an Adverse Event of Headache | 1.9 | 1.2 |
An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of fatigue recorded on the VRC during the first 14 days after vaccination was recorded.
| Percentage of participants | Revaccination Group | Primary Vaccination Group |
|---|---|---|
| Percentage of Participants With an Adverse Event of Fatigue | 1.2 | 0.0 |
Collected over All adverse events: up to 14 days after vaccination; deaths and vaccine-related serious adverse events: up to 36 days after vaccination. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Revaccination Group | — | 4/161 (2.5%) | 113/161 (70.2%) |
| Primary Vaccination Group | — | 0/81 (0%) | 41/81 (50.6%) |
| Event | Revaccination Group | Primary Vaccination Group |
|---|---|---|
| PyrexiaGeneral disorders | 1/161 | 0/81 |
| Herpes virus infectionInfections and infestations | 1/161 | 0/81 |
| Femoral neck fractureInjury, poisoning and procedural complications | 1/161 | 0/81 |
| Bronchitis chronicRespiratory, thoracic and mediastinal disorders | 1/161 | 0/81 |
| Event | Revaccination Group | Primary Vaccination Group |
|---|---|---|
| Injection-site painGeneral disorders | 101/161 | 38/81 |
| Injection-site swellingGeneral disorders | 62/161 | 14/81 |
| Injection-site erythemaGeneral disorders | 57/161 | 12/81 |
| Injection-site pruritusGeneral disorders | 11/161 | 2/81 |
| PyrexiaGeneral disorders | 11/161 | 1/81 |
One participant in the Primary Vaccination Group was withdrawn from the study before vaccination because of a protocol violation. Baseline Characteristics are based on the Full Analysis Set: participants who received at least one vaccination.
| Age, Continuous(Years) | Revaccination Group | Primary Vaccination Group | Total |
|---|---|---|---|
| Mean | 78.8 ± 4.8 | 78.2 ± 5.0 | 78.6 ± 4.8 |
| Sex: Female, Male(Participants) | Revaccination Group | Primary Vaccination Group | Total |
|---|---|---|---|
| Female | 94 | 46 | 140 |
| Male | 67 | 35 | 102 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Oct 2014 to primary completion in Apr 2015, 5 months.
Results were first posted in Feb 2016, 10 months after primary completion.
Of 21 phase 4 interventional studies under Pneumococcal Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 44. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 23-valent pneumococcal capsular polysaccharide vaccine